Quanterix Corp Files 2023 10-K Amendment

TL;DR

Quanterix filed its 2023 10-K amendment on Dec 26, 2024. Check financials.

AI Summary

Quanterix Corp filed an amendment to its 2023 10-K on December 26, 2024, reporting financial results for the fiscal year ending December 31, 2023. The filing provides updated details on the company's financial performance and operations. Quanterix Corp is a Delaware-incorporated company specializing in laboratory analytical instruments.

Why It Matters

This amendment provides updated financial information for Quanterix Corp's 2023 fiscal year, which is crucial for investors and analysts to assess the company's performance and make informed decisions.

Risk Assessment

Risk Level: low — This filing is an amendment to a previous 10-K, primarily for updating financial information, and does not appear to introduce new significant risks.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the financial statements in the 10-K/A.)
• 2024-12-26 — Filing Date (The date this amended 10-K was submitted to the SEC.)

Key Players & Entities

• Quanterix Corp (company) — Filer of the 10-K/A
• 2023-12-31 (date) — Fiscal year end for the reported period
• 2024-12-26 (date) — Filing date of the 10-K/A
• 0001503274-24-000025 (other) — Accession number for the filing

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share QTRX The Nasdaq Glo

Filing Documents

• qtrx-20231231.htm (10-K/A) — 5184KB
• ex231-restatementqtrxx2023.htm (EX-23.1) — 6KB
• ex311-restatementqtrxx2023.htm (EX-31.1) — 9KB
• ex312-restatementqtrxx2023.htm (EX-31.2) — 10KB
• ex321-restatementqtrxx2023.htm (EX-32.1) — 5KB
• 0001503274-24-000025.txt ( ) — 27308KB
• qtrx-20231231.xsd (EX-101.SCH) — 80KB
• qtrx-20231231_cal.xml (EX-101.CAL) — 106KB
• qtrx-20231231_def.xml (EX-101.DEF) — 546KB
• qtrx-20231231_lab.xml (EX-101.LAB) — 792KB
• qtrx-20231231_pre.xml (EX-101.PRE) — 795KB
• qtrx-20231231_htm.xml (XML) — 7941KB

, Item 1A. Risk Factors

Part I, Item 1A. Risk Factors

, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

, Item 7A. Quantitative and Qualitative Disclosures about Market Risk

Part II, Item 7A. Quantitative and Qualitative Disclosures about Market Risk

, Item 8. Financial Statements and Supplementary Data

Part II, Item 8. Financial Statements and Supplementary Data

, Item 9A. Controls and Procedures

Part II, Item 9A. Controls and Procedures

, Item 15. Exhibits and Financial Statement Schedules

Part IV, Item 15. Exhibits and Financial Statement Schedules Except as described above, this Amended Report does not amend, update, or change any other disclosures in the Original Report. Among other things, except as related to the Restatement, forward looking statements made in the Original Report have not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Report, and such forward looking statements should be read in their historical context. As such, this Amended Report speaks only as of the date the Original Report was filed, and the Company has not undertaken herein to amend, supplement, or update any information contained in the Original Report to give effect to any subsequent events. Accordingly, this Amended Report should be read in conjunction with the Original Report, including any other filings with the SEC. This Amended Report also contains updated reports of Ernst & Young, LLP ("EY"), the Company's independent registered public accounting firm, on the consolidated financial statements as of December 31, 2023 and 2022 and for each of the three years in the period ended December 31, 2023 and on the effectiveness of the Company's internal control over financial reporting as of December 31, 2023, and an updated consent of EY. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), new certifications by the Company's Chief Executive Officer (as principal executive officer) and Chief Financial Officer (as principal financial officer) are filed herewith as Exhibits 31.1, 31.2 and 32.1 to this Amended Report pursuant to Rule 13a-14(a) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350). Table of Contents QUANTERIX CORPORATION INDEX TO FORM 10-K/A Note Regarding Forward-Looking Statements Page PART I Item 1A. Risk Factors (As Restated) 1 PART II Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations (As Restated)

Management's Discussion and Analysis of Financial Condition and Results of Operations (As Restated) 20 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk (As Restated)

Quantitative and Qualitative Disclosures about Market Risk (As Restated) 34 Item 8.

Financial Statements and Supplementary Data (As Restated)

Financial Statements and Supplementary Data (As Restated) 35 Item 9A.

Controls and Procedures (As Restated)

Controls and Procedures (As Restated) 35 PART IV Item 15. Exhibits and Financial Statement Schedules (As Restated) 40

Signatures

Signatures 43 Consolidated Financial Statements (As Restated) F- 1 i Table of Contents Unless the context otherwise requires, the terms "Quanterix," the "Company," "we," "it," "us," and "our" in this Amended Report refer to Quanterix Corporation and its consolidated subsidiaries. Note Regarding Forward-Looking Statements This Amended Report contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties. All statements other than statements of historical facts contained in this Amended Report are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would," or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: the implementation of our business model and strategic plans for our business, products and services, especially following the restructuring and strategic realignment we commenced in the third quarter of 2022; the potential size of the markets and fields addressable by our Simoa technology platforms; the commercialization and adoption of our existing products and services and the success of our new product and service offerings; our estimates regarding expenses, future revenues, capital requirements, and our needs for additional financing; risks related to the Restatement of our Consolidated Financial Statements included in the Amended Filings, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation; our ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including our ability to remediate exi

RISK FACTORS

ITEM 1A. RISK FACTORS The following risk factors and other information included in this Amended Report should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Refer to page ii of this Amended Report for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. Risk Factor Summary Our business is subject to numerous risks and uncertainties. The following summary highlights some of the risks to be considered with respect to our business and prospects. This summary is not complete and the risks summarized below are not the only risks we face. Readers should review and carefully consider the risks and uncertainties described in more detail below, which includes a more complete discussion of these risks. Failure to remediate material weaknesses in, or inherent limitations associated with, our internal control over financial reporting have resulted in, and in the future could result in, material misstatements in our financial statements. The Restatement of our financial statements may affect stockholder and investor confidence in us or harm our reputation, and may subject us to additional risks and uncertainties, including increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions or investigations. Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, which could cause the value of our common stock to fluctuate or decline significantly. We have incurred annual losses since we were formed and expect to incur losses in the future. We cannot be certain that we will a

View Full Filing

View this 10-K/A filing on SEC EDGAR